Announcements

Edward Kaftan, PhD, Appointed Associate Cancer Center Director for Research Affairs

We are pleased to announce the appointment of Edward Kaftan, PhD, to Associate Director Designate for Research Affairs at Yale Cancer Center. On January 1, 2022, Dr. Kaftan will transition to Associate Cancer Center Director for Research Affairs at Yale Cancer Center following the retirement of Robert Garofalo, PhD. Dr. Kaftan has guided our translational science efforts for Yale Cancer Center for nearly a decade, emphasizing an inclusive culture and fostering research engagement and career advancement for our entire Yale Cancer Center community. His proven leadership will be an asset as he begins to lead our Research Affairs team and our Cancer Center Support Grant (CCSG) efforts.

Dr. Kaftan joined Yale School of Medicine in 2012 as an Associate Research Scientist in the Department of Pharmacology, and in 2014 joined the Section of Medical Oncology. For the last seven years, he has worked closely with Roy S. Herbst, MD, PhD, to lead Yale Cancer Center’s Translational Research Office; earlier this year, Dr. Kaftan was named Assistant Cancer Center Director for Translational Science. Prior to joining Yale, he worked in research at Wyeth Research, Pfizer Pharmaceuticals, and R.W. Johnson Pharmaceutical Research Institute. He is a graduate of Rensselaer Polytechnic Institute and earned his PhD in Cell Biology from the University of Connecticut.

We are incredibly grateful to Dr. Garofalo for his insight and leadership as Associate Director for Research Affairs for Yale Cancer Center since 2015. He and his team expertly led us through our CCSG renewal in 2018 and have helped to support the exponential growth of our research enterprise. We appreciate Dr. Garofalo’s assistance and mentorship over the coming months and look forward to celebrating his retirement prior to his departure in the new year.

Dr. Christi Kim Joining Waterford from the desk of
Nita Ahuja, MD, MBA, FACS
Interim Director, Yale Cancer Center
Interim Physician-in-Chief, Smilow Cancer Hospital

News Center

Dr. Anna Arnal Estapé Shares Why She Works in Cancer Research

Read More

Yale Cancer Center Study Shows Stem-Like T Cells Could Aid Immunotherapy in
Dr. Christi Kim Joining Waterford Care Center

Christi Kim, MD, has been named an Assistant Professor of Clinical Medicine (Medical Oncology) and will join the Smilow Cancer Hospital Care Center in Waterford, CT on October 1. Dr. Kim is a general medical oncologist with special interests in the care of patients with gynecologic cancers, breast cancer, and lymphoma. She received her medical degree from St. George’s University School of Medicine and completed both a fellowship and residency at Stony Brook University Hospital, where she joined the faculty as an Assistant Professor of Medicine.

Dr. Kim is an active member of the Gynecologic Oncology Group (GOG) Foundation and of the Society of Gynecologic Oncology (SGO) Clinical Practice Committee. She recently co-authored the SGO clinical practice guideline and has served on advisory boards for The Caris Precision Oncology Alliance Working Group in gynecologic cancer. Dr. Kim has published in several journals including Blood, Journal of the American Society of Nephrology, and presented ASCO abstracts related to proteinuria with bevacizumab.

JH Milstone Fund 2021 Awardees Announced

The inaugural awardees of the JH Milstone Fund are Matthew McConnell, MD, Instructor of Medicine (Digestive Diseases), and Sean Gu, MD/PhD, Clinical Fellow in the Department of Laboratory Medicine (pictured left to right). Their projects are titled, respectively, The role of platelets in the pathogenesis of alcohol-related liver disease and High-throughput Diagnostic Evaluation of Patients with Platelet Disorders by Mass Cytometry.

The JH Milstone Fund was established to support early-stage investigators and innovative research and education in thrombosis, thrombolysis, and hemostasis in memory of JH Milstone, MD, by his son, Leonard M. Milstone, MD ’70, Professor Emeritus of Dermatology, and daughter-in-law, Ellen B. Milstone, MD ’69. Robert Bona, MD, Director of Smilow Cancer Hospital’s Benign Hematology Program, and Stephanie Halene, MD, PhD, Chief of Hematology, commented, “The fund, in honor of J. Haskell Milstone, MD, to support research in blood coagulation, provides important support and encouragement for bright minds to enter this field. We are immensely grateful for the generosity of the Milstone family.”

Like T Cells Could Aid Immunotherapy in Cancer Treatment

Dr. Natalia Buza Shares Why She Works in Cancer Research

Dr. Manoj Pillai Shares Why He Works in Cancer Research

Yale Cancer Center and Leading Cancer Centers Urge Vaccination to Protect Against HPV and Other Diseases

Dr. Elizabeth Prsic Shares Why She Works in Cancer Research
encouragement for bright minds to enter this field. We are immensely grateful for this generous gift."

Dr. J. Haskell Milstone was a Professor of Pathology at Yale from 1947-1977. He taught pathology and blood coagulation to a generation of medical students and residents and advocated strongly for better treatment for those with hemophilia. This annual fund honors Dr. Milstone’s seminal work in coagulation and will continue to support generations of researchers. We congratulate Drs. McConnell and Gu and look forward to their future successes!

Notables

Lawrence + Memorial Hospital has received full accreditation from the Commission on Cancer (CoC) with four commendations. Thank you to the extraordinary leadership of Mary Ann Nash, MBA, MS, RD, CSO, Administrative Director, Oncology Services, and the entire physician, nursing, and supportive care team at our Smilow Cancer Hospital Care Center in Waterford for their incredible support through this process. The Cancer Program at L+M has now achieved 23 years of accreditation.

Navid Hafez, MD, MPH, Assistant Professor of Medicine (Medical Oncology), has been awarded a Bristol Myers Squibb Foundation/National Medical Fellowships Diversity in Clinical Trials Career Development Program (BMSF DCTCDP) Award through the American Association of Cancer Research. The BMSF DCTCDP will provide two years of sponsorship, training, and mentoring to support development as a clinical investigator advancing health equity through research and mentoring.

Mehra Golshan, MD, MBA, Clinical Director of the Breast Program and Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital, has been appointed as Executive Vice Chair of Operations for the Department of Surgery. As Executive Vice Chair of Operations, Dr. Golshan will function as a liaison to the Chair—and in support of Delivery Network Hospital leadership, Vice Chairs, Division Chiefs, and Section Chiefs—to promote the efficient and timely execution of day-to-day matters across the clinical and academic missions.

Maryam Lustberg, MD, MPH, Chief of Breast Medical Oncology and Director of The Breast Center at Smilow Cancer Hospital, presented at a Breast Cancer Education Tumor Board Program for colleagues in Latin America on August 26 on Quality of life in Patients with Metastatic Breast Cancer.

R. Peter Manes, MD, Associate Professor of Surgery (Otolaryngology), has been appointed as Medical Director for Ambulatory Operations for the Department of Surgery. In his new role, Dr. Manes will play a key role in the growth and development of programs and initiatives across the Department of Surgery’s outpatient clinics.

Congratulations to the following nursing leaders who have received promotions or have recently joined Smilow Cancer Hospital:

Sandy Morgan, RN, Patient Services Manager for NP7 at our Yorktown Heights Hospital

Confirmation class at Christ Church, Westerly. Thank you for the beautiful addition to our halls, and generous gift!
Several faculty in medical oncology will present their expertise in a **Best of Oncology ASCO Direct Conference** next month, including Lajos Pusztai, MD, DPhil, Professor of Medicine (Medical Oncology), Hari Deshpande, MD, Associate Professor of Medicine (Medical Oncology) and Aarti Bhatia, MD, MPH, Assistant Professor of Medicine (Medical Oncology).

### Diversity, Equity, and Inclusion

September is **Women in Medicine Month**, honoring physicians who have offered their time, wisdom, and support to advance women with careers in medicine. Celebrate Women in Medicine Month on Tuesday, September 21, 6:30 – 7:30 AM, with a special **negotiation workshop** presented on YouTube by the American Medical Association by Anees B. Chagpar, MD, MSc, MPH, MA, MBA, FACS, the 2020 recipient of the Joan F. Giambalvo Fund for the Advancement of Women. Dr. Chagpar will discuss her research focused on the creation and assessment of a virtual negotiation workshop for women physicians as well as provide tips and advice to guide the negotiation process.

**amplifyHERscience**, a new program of Yale’s Office of Cooperative Research, is inviting applications for a "shark tank" style event on September 23 at 12pm, in which women entrepreneurs will pitch their startup ideas to business professionals. In this case, co-organizers are calling it the Women Innovators from Yale University Dolphin Tank, a “friendly-feedback” session in which participants will receive constructive advice and practical insights following 3 to 5 minute pitches. Presenters must be women. **Applications** to pitch your innovation are due by midnight on September 9. All attendees are welcome regardless of affiliation, industry, or gender. **RSVP to join the audience** at no cost to watch the action live, and for a chance to virtually network.

In a recent piece in the **Journal of the National Comprehensive Cancer Network**, Diversity, Equity, and Representativeness: Coming to Terms With the Henrietta Lacks Act, Daniel J. Boffa, MD, Keith B. Churchwell, MD, and Richard C. Maduka, MD share how equity in cancer care begins with representativeness in cancer research. The Henrietta Lacks Act was designed to enhance the representativeness of minoritized and traditionally underrepresented populations in the studies that define best practices in cancer care. Their intent in the article was to both discuss the potential impact of the Act on cancer research and cancer care, as well as to offer simple definitions of key terms to encourage more people to engage in the critical conversations around equity. **Read More**

### Employee Profile: Lisa Muscillo

Addition to our halls, and generous gift!

**Our 3-D mammography and breast imaging van will be at the Uncasville Medical Center at Mohegan Sun on a rotating schedule this fall to provide women with access to the latest breast imaging technology.**

To schedule an appointment at the mobile unit, call (203) 688-1010 or 833-772-0003.

**Our oncology pharmacy team serves as a key member of all multidisciplinary cancer care teams across the entire Smilow Cancer Hospital Network, and includes specially**
Employee Profile: Lisa Muscillo

They are the people we have all interacted with when arriving to and checking out after a doctor’s appointment. The friendly face who is there to greet us after an exam or procedure, and the reassuring voice on the phone who calls to confirm an upcoming appointment. On the fourth floor of the North Haven Medical Center, this person is Lisa Muscillo, one of the many individuals who interacts with patients as they arrive and depart and everything in-between.

Lisa is a Patient Financial Access Specialist. She returns patient phone calls, schedules follow-up appointments, checks patients in and out, and completes referrals. In addition to these responsibilities, Lisa also serves as the key scheduler for hematology-oncology infusions, managing the patients for 10-12 providers on the fourth floor. She schedules biopsies, port placements and removals, secures pre-authorizations for elective chemotherapy admissions, and sets up anywhere from 26-32 infusion chairs every day for chemotherapy and/or platelet infusions.

From the moment she arrives at work, she has no seconds to spare, thriving on the busy pace her job requires but always making time to help coworkers. During the peak of COVID, Lisa maintained her on-site work schedule, adding weekend hours at COVID sites for testing and vaccine administration, and she wouldn’t have it any other way. “I’m here to do my job and help patients improve their quality of life,” says Lisa. “I’m a people person and I love interacting with our patients; I love our team — they’re the bomb, from our doctors to everyone in the lab, to our greeters and transporters, and the support I get from the PFAS team makes very difficult times a lot less stressful.”

Denise Armstrong, LCSW, oncology clinical social worker based at North Haven Medical Center says, “Lisa is such a dedicated worker. I admire her tenacity and willingness to ALWAYS put patients first. Lisa is my go-to person for anything work or patient related, always getting back to me right away…I love her work ethic!”

Recent Publications


Future Research in Cancer Survivorship.

Journal of Cancer Survivorship, Online ahead of print.


Conventional Hepatic Volumetry May Lead to Inaccurate Segmental Hospital Network, and includes specially trained oncology pharmacists, and certified pharmacy techs. They work collaboratively with our physicians and other providers to ensure safe, effective, and timely cancer care. They can also assist with potential high out-of-pocket costs for chemotherapy and cancer care medications, so that patients can focus on their physical and mental health.

Diversity in cancer research is critical for success, says Dr. John Onofrey, a member of Yale Cancer Center and Assistant Professor of Radiology & Biomedical Imaging and of Urology. "Optimal solutions cannot be found from looking at one set of data. One must have diverse samples that are representative of life."

The Cancer Signaling Networks Research Program welcomes Peter Humphrey, MD, PhD, Professor of Pathology and Director of Genitourinary Pathology. The Cancer Signaling Networks Program brings together world-class investigators across Yale Cancer Center to understand fundamentals of key pathways that drive carcinogenesis and cancer progression, with the goal of enabling development and improvement of effective
Conventional Hepatic Volumetry May Lead to Inaccurate Segmental Yttrium-90 Radiation Dosimetry. 
Online ahead of print. 

Soble W, Tymon-Rosario J, Huang G. 
touchREVIEWS in Oncology & Haematology. 2021;17(1):23-27 
Read More

Shammas RL, Fish LJ, Sergesketter AR 2nd, Offodile AC, Phillips BT, Oshima S, Lee CN, Hollenbeck ST, Greenup RA. 
Annals of Surgical Oncology, Online ahead of print. 
Read More

Trends in Breast Cancer Screening Costs Among Privately Insured Women Aged 40 to 64 Years. 
JAMA Internal Medicine, Online ahead of print. 
Read More

PD-L1 Tumor Proportion Score and Overall Survival from First-line Pembrolizumab in Patients with Nonsquamous Versus Squamous Non-Small Cell Lung Cancer. 
Journal of Thoracic Oncology, Online ahead of print. 
Read More

DHE50815A, a Novel Antibody-drug Conjugate Targeting HER2/Neu, is Highly Active Against Uterine Serous Carcinomas In Vitro And In Vivo. 
Gynecologic Oncology, Online ahead of print. 
Read More

Berger ER, Park T, Saridakis A, Golshan M, Greenup RA, Ahuja N. 
Immunotherapy Treatment for Triple Negative Breast Cancer. 
Pharmaceuticals, 14(8):763. 
Read More

Arora G, Joshi J, Mandal RS, Shrivastava N, Virmani R, Sethi T. 
Pathogens, 10(8):1048. 
Read More

Marczyk M, Polańska J, Wojcik A, Lundholm L. 
Analysis of the Applicability of microRNAs in Peripheral Blood Leukocytes as Biomarkers of Sensitivity and Exposure to Fractionated Irradiation. 
Pathogens, 10(4):368. 
Read More

According to Dr. Xavier Llor, knowledge is power when it comes to cancer research and knowing your risk of developing cancer. #ThisIsWhy #NothingWillStopUs

Our #SmilowStar is Fae Willett, RN, who retired recently after working for 30 years as an Oncology Nurse in the Yale New Haven Health System. Fae is a warrior who survived breast cancer four times and never let her diagnoses or treatment get her down. She is always positive! She continued to be an inspiration to her patients and colleagues and she shared personal experiences with new and active patients, which eased their
Leukocytes as Biomarkers of Sensitivity and Exposure to Fractionated Radiotherapy towards Breast Cancer.

Read More

Pointer TC, Gorelick FS, Desir GV.
*Renalase: A Multi-Functional Signaling Molecule with Roles in Gastrointestinal Disease.*
*Cells, 10*(8):2006.

Read More

Uezono H, Nam D, Kluger HM, Szol M, Hurwitz M, Yu JB, Chiang VL.
*Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases.*

Read More

*Phase II Study of Durvalumab Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP substudy S1400F, NCT03373760).*
*Journal for ImmunoTherapy of Cancer, 9*(8):e002973.

Read More

Lopez L 3rd, Dhodapkar M, Gross CP.
*US Nonprofit Hospitals’ Community Health Needs Assessments and Implementation Strategies in the Era of the Patient Protection and Affordable Care Act.*
*JAMA Network Open, 4*(8):e2122237.

Read More

*Annals of Surgical Oncology, Online ahead of print.*

Read More

*Bayesian Structural Time Series for Biomedical Sensor Data: A Flexible Modeling Framework for Evaluating Interventions.*
*PLOS Computational Biology, 17*(8):e1009303, Online ahead of print.

Read More

Ananth, P.
*Reenvisioning End-of-Life Care Quality Measurement for Adolescents and Young Adults With Cancer-Novel Patient-Centered Indicators and Approaches.*
*JAMA Network Open, 4*(8):e2122323.

Read More

Fae’s bubbly personality relaxed our patients. She belongs to a women’s chorus, Harmony on the Sound, and always brought music to the treatment area where her patients would sing along with her. Fae spearheaded the annual Making Strides Against Breast Cancer team from Bridgeport Hospital and our Smilow Cancer Hospital Care Centers in Trumbull and Fairfield, along with our families and patients. The teams in Trumbull and Fairfield will miss Fae—she was a joy to work with and loved by all, always putting our patients first and going above and beyond to accommodate them, even if it meant staying beyond her scheduled time.

Thank you to Connecticut Sun for their support of breast cancer care at Smilow Cancer Hospital! Team members from The Breast Center at Smilow Cancer Hospital had a great time at last week’s game and celebrated with a center court check presentation.

— at Mohegan Sun.

Efficacy of Enzalutamide in Subgroups of Men with Metastatic Hormone-sensitive Prostate Cancer Based on Prior Therapy, Disease Volume, and Risk.
*Prostate Cancer and Prostatic Diseases*, Online ahead of print.


Vaccine-induced ErbB (EGFR/HER2)-specific immunity in Spontaneous Canine Cancer.
*Translational Oncology*, 14(11):101205, Online ahead of print.

Sznol, M.

TIL in Melanoma-Similar Approaches, Different Results, Unanswered Questions.

Vazquez E, Gouraud H, Naudet F, Gross CP, Krumholz HM, Ross JS, Wallach JD.

*Clinical Trials*, Online ahead of print.

Talty R, Bosenberg M.

The Role of Ferroptosis in Melanoma.

Kim CS, Turocy T, Moon G, Shine EE, Crawford JM.

Escherichia coli-Derived γ-Lactams and Structurally Related Metabolites Are Produced at the Intersection of Colibactin and Fatty Acid Biosynthesis.
*Organic Letters*, Online ahead of print.

Chagpar AB, Berger E, Alperovich M, Zanieski G, Avraham T, Lannin DR.

*Annals of Surgical Oncology*, Online ahead of print.


Real-world Association of HER2/ ERBB2 concordance with Trastuzumab Clinical Benefit in Advanced Esophagogastric Cancer.
*Future Medicine*, Online ahead of print.

Adam Brenner, a master’s degree candidate at UConn, hosted the inaugural Stuart Brenner Memorial Golf Outing at Lyman Orchards Golf Club in Middlefield, CT on July 31. The tournament, in memory of Adam’s father and in gratitude for the extraordinary care received, raised over $13,000 for our Oncology Social Work Fund. Sonia Grizzle, Executive Director for Smilow Cancer Hospital, accepted the donation on behalf of the oncology social work team and our patients. We are so appreciative of Adam’s enormous effort for this very successful event!
Funding and Award Opportunities

Time-Sensitive Obesity Policy and Program Evaluation (R01)
This FOA establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors and/or weight outcomes to prevent or reduce obesity.

**Application Deadline:** September 22, 2021

Charles H. Hood Foundation: Child Health Research Awards Program
This award is to support newly independent faculty, provide the opportunity to demonstrate creativity, and assist in the transition to other sources of research funding.

**Application Deadline:** September 22, 2021

The Hamoui Foundation/LUNGevity Award for RET-Positive Lung Cancer Research
The goal of the award is to fund impactful proposals in the RET-positive lung cancer space with direct clinical implications within 1-2 years.

**Application Deadline:** September 17, 2021

RETpositive/LUNGevity Award for RET-positive Lung Cancer Research
This award supports research that has a direct impact on the outcomes of patients with advanced RET-positive lung cancer; however, innovative proposals that address other unmet needs in the RET-positive lung cancer space are also invited for submission.

**Application Deadline:** September 17, 2021

NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort (U54)
This RFA aims to facilitate institutions in building a community of scientists by recruiting and supporting a cohort of early-career faculty who have demonstrated a commitment to diversity and inclusive excellence.

**Application Deadline:** September 24, 2021

National Comprehensive Cancer Network & Eli Lilly Biomarker Driven Therapy in Lung and Thyroid Cancers
The NCCN and Eli Lilly are seeking proposals to improve patient care and outcomes in lung and thyroid cancers. Multiple factors contribute to the complexity of treating these diseases, including stage and histology, personalization of systemic therapy based on molecular profiles, patient factors, and therapeutic landscape.

**Application Deadline:** September 28, 2021

Cancer Research Institute Irvington Postdoctoral Fellowship Program
Cancer Research Institute Irvington Postdoctoral Fellowship Program
Supports qualified young scientists at leading universities and research centers around the world who wish to receive training in fundamental immunology or cancer immunology. Proposals should include studies that directly impact our understanding of the immune system's role in cancer.

**Application Deadline:** October 1, 2021
Read More

**Technology Development for Single-Molecule Protein Sequencing (R01)**
This FOA solicits grant applications to catalyze major advances in single-molecule protein sequencing and single cell proteome analysis through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost, and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general.

**Application Deadline:** October 1, 2021
Read More

**Rally Foundation Collaborative Pediatric Cancer Research Awards Program**
Rally helps fund the most promising research initiatives, and invests in projects and innovative approaches to research which could lead to advanced studies or clinical trials.

**Application Deadline:** October 1, 2021
Read More

**The Role of Work in Health Disparities in the U.S. (R01)**
The purpose of this FOA is to support innovative population-based research that can contribute to identifying and characterizing pathways and mechanisms through which work or occupation influences health outcomes and health status among populations with health and/or health care disparities, and how work functions as a social determinant of health.

**Application Deadline:** October 5, 2021
Read More

**Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01)**
Through this FOA, the NCI invites R01 grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of these modalities in the characterization of therapy response and/or emergence of treatment resistance.

**Application Deadline:** October 5, 2021
Read More

**Molecular Imaging of Inflammation in Cancer (R01)**
The purpose of this FOA is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo.

**Application Deadline:** October 5, 2021
Read More

**Cancer Target Discovery and Development (CTD2) (U01)**
Through this FOA, the NCI will support the program Cancer Target Discovery and Development. CTD2 is focused on efforts that advance cancer research, discuss the potential impact of the Henrietta Lacks Enhancing Cancer Research Act @JNCCN "The Act is a good step toward addressing a great need, but few journeys are completed in a single step."

**Calendar**

**Yale Cancer Answers**
September 5; 7:30 PM
NPR
Lymphoma and Leukemia Awareness
Terri Parker, MD
Learn More

**Genetics Department Seminar Series**
September 7; 11:00 AM
Janghoo Lim, PhD
Learn More

**Yale Center for Molecular and Systems Metabolism (YMSM)**
September 7; 11:00 AM
Macronutrient Effects on Food Intake and Body Weight Regulation
Dr. John Speakman
Learn More

**NCI Blue Ribbon Panel Report Anniversary**
September 9; 12:00 PM
Reflections, Progress, and Potential of the Cancer Moonshot
Learn More

**Cancer Genetics and Prevention Program**
September 9; 2:30 PM
Sharing Genetic Test Results and Cascade Genetic Testing in Families with Known Hereditary Cancer Risk
Tanaya Shroff, MS, CGC
Learn More

**Center for GI Cancers Weekly Seminar – Journal Club**
September 9; 4:15 PM
PRODIGE-23 Trial
Justin Persico, MD
Learn More

**Surgery Grand Rounds**
September 10; 7:30 AM
State of the Department AY22
Nita Ahuja, MD, MBA, FACS
Learn More
CTD2 is focused on efforts that advance cancer research by bridging the knowledge gap between the large volumes of comprehensive molecular characterizations of many cancer types and studies of the underlying etiology of cancer development, progression, and/or metastasis.

**Application Deadline:** October 6, 2021

**Read More**

**Melanoma Research Alliance RFPs**
The MRA is pleased to announce RFPs for pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, staging, and treatment.

**Team Science Award LOI Due:** October 6, 2021

**Young Investigator Award Checklist Due:** November 3, 2021

**Pilot Awards Due:** November 3, 2021

**Read More**

**Metabolic Dysregulation and Cancer Risk Program, Research Grants: a Transdisciplinary Approach to Obesity-Associated Research (U01)**
The NCI invites research grant applications for transdisciplinary studies that will enhance our knowledge of the dynamics and underlying mechanisms that link obesity, metabolic dysregulation and increased cancer risk as part of the Metabolic Dysregulation and Cancer Risk Program. Through this FOA, the Metabolic Dysregulation and Cancer Risk Program will focus on metabolic dysregulation as the key process linking obesity with cancer risk.

**Application Deadline:** October 6, 2021

**Read More**

**Coordinating Center for the Metabolic Dysregulation and Cancer Risk Program: A Transdisciplinary Approach to Obesity-Associated Cancer Research (U24)**
Through this FOA, the NCI will support a Coordinating Center to facilitate coordination across the consortium of multiple individual research project grants for the Metabolic Dysregulation and Cancer Risk Program whose overarching goal is to enhance our knowledge of the dynamics, and underlying mechanisms, that link obesity, metabolic dysregulation, and increased cancer risk.

**Application Deadline:** October 6, 2021

**Read More**

**Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54)**
The purpose of this FOA is to solicit applications for Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54). The overall goal of the CAP-IT Program is to establish an agile and effective network infrastructure to undertake collaborative research focusing on precision cancer prevention and interception, with the overarching goal of discovering molecularly or immunologically targeted agents designed to prevent or intercept the oncogenic process in higher-risk populations.

**Application Deadline:** October 7, 2021

**Read More**

**Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center (CAP-IT DRCC) (U24)**
The purpose of this FOA is to solicit Applications for the Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center (CAP-IT DRCC) (U24)

**Center for Methods in Implementation and Prevention Science (CMIPS) Seminar Series**

**Bereavement Seminar**

**Dissecting Triple Negative Breast Cancer**

**Yale Head and Neck SPORE's Monthly Meeting**

**Pathology Grand Rounds**

**Center for GI Cancers Weekly Seminar**

**Digestive Diseases Physiopathology Seminar**

**Familial Colon Cancer Syndromes**

**NPR**

**Ovarian Cancer Awareness Month**

**Yale Cancer Answers**

** Genetics Department Seminar Series**

**Understanding and Managing Grief: How Long Am I Going to Feel Like This?**

**Center for GI Cancers Weekly Seminar**

**Learn More**
Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center (CAP-IT DRCC) (U24). The overall goal of this FOA and the companion FOA (U54 CAP-IT Specialized Centers, RFA-CA-21-038) is to establish an agile and effective network infrastructure to undertake collaborative research focusing on precision cancer prevention and interception, with the overarching goal of discovering molecularly or immunologically targeted agents designed to prevent or intercept the oncogenic process in higher-risk populations.

**Application Deadline:** October 7, 2021

### Program on the Origins of Gastroesophageal Cancers (R01)

This FOA is to request applications for the Program on the Origins of Gastroesophageal Cancers (R01). This new program will build on recent molecular classifications of gastroesophageal cancers, significant understanding of their cancer genomics, and advances in stem cell research to examine and define how these related cancers initially evolve at the cellular level.

**Application Deadline:** October 8, 2021

### Coordinating Center for the Program on the Origins of Gastroesophageal Cancers (U24)

This FOA is to request applications for the Coordinating Center, Program on the Origins of Gastroesophageal Cancers (U24). This new program will build on recent molecular classifications of gastroesophageal cancers, significant understanding of their cancer genomics, and advances in stem cell research to examine and define how these related cancers initially evolve at the cellular level.

**Application Deadline:** October 8, 2021

### NCI F99/K00 Predoctoral to Postdoctoral Fellow Transition Award

This award supports outstanding PhD and other Research Doctoral candidates to complete their dissertation research training (F99 phase) and transition in a timely manner to mentored, cancer-focused postdoctoral career development research positions (K00 phase).

**Letter of Intent Due:** October 10, 2021

### AACR Anna D. Barker Basic Cancer Research Fellowship

This award supports postdoctoral or clinical research fellows to establish a successful career path in cancer research.

**Application Deadline:** October 14, 2021

### CRI Irvington Postdoctoral Fellowship to Promote Racial Diversity

CRI invites applications from candidates who identify as Black or African American, Hispanic or Latino/a American, or American Indian or Alaska Native. CRI is seeking hypothesis-driven, mechanistic studies in both immunology and tumor immunology that aim to directly impact our understanding of the immune system's role in cancer.

**Application Deadline:** October 21, 2021

### Debbie's Dream Foundation Career Development Award for Gastric Digestive Health Virtual CME Series

September 16; 5:00 PM

**IBD**

Jill Gaidos, MD & Vikram Reddy, MD, PhD, FACS, FASCRS

Learn More

### Submissions

Please submit your recent publications, awards, and grant announcements to:

Renee Gaudette
Director, Public Affairs and Communications
Debbie’s Dream Foundation Career Development Award for Gastric Cancer Research
This award supports junior faculty to conduct gastric cancer research and to establish a successful career path in this field.
**Application Deadline:** October 28, 2021
Read More

Research Supplements to Promote Re-Entry and Re-integration into Health-Related Research Careers
The goal of this program is to provide support for a mentored research training experience for individuals with high potential to re-enter or re-integrate into an active research career, after an interruption for family responsibilities or other qualifying circumstances.
**First Available Due Date:** November 1, 2021
Read More

Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54)
The purpose of this FOA is to solicit applications for U54 Research Centers to form the Radiation Oncology-Biology Integration Network (ROBIN). The cadre of ROBIN Centers created through this FOA will establish an agile and effective national radiation oncology network infrastructure that collectively address critical hypothesis-based translational research knowledge gaps on the biological basis of responses in cancer patients who undergo radiation treatments.
**Application Deadline:** November 1, 2021
Read More

Acquired Resistance to Therapy Network (ARTNet; U54)
The ARTNet FOA is a new funding opportunity that builds upon the Drug Resistance and Sensitivity Network (DRSN, RFA-CA-17-009) to focus study on the mechanistic basis of acquired resistance to cancer therapies and disease recurrence.
**Application Deadline:** November 1, 2021
Read More

Coordinating and Data Management Center for Acquired Resistance to Therapy Network (ARTNet; U24)
The overarching goal of the ARTNet is to bridge basic, pre-clinical, and translational research along the tumor-tumor microenvironment continuum to inform new strategies that can be better translated to overcome significant challenges in acquired resistance to cancer therapies. The Coordinating Center will assemble the appropriate infrastructure to facilitate and implement the administrative, outreach, collaborative, and data management activities of the ARTNet.
**Application Deadline:** November 1, 2021
Read More

Cancer Research Institute Clinical and Laboratory Integration Program (CLIP) Immunotherapy
CLIP supports pre-clinical and translational research that can be directly applied to optimizing cancer immunotherapy in the clinic. CLIP grants are awarded to qualified scientists exploring clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies.
**Letter of Intent Due:** November 1, 2021
Read More
Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC) (U01)
The purpose of this FOA is to solicit applications for U01 Research Projects to form the NCI-led PDAC Stromal Reprogramming Consortium (PSRC). The overarching objective of the PSRC is to develop a comprehensive understanding of PDAC tumor progression, its microenvironment (TME) as a tumor fate determinant and the reciprocal tumor-TME interactions that drive clinical outcomes.

**Application Deadline:** November 1, 2021

Read More

NCI Research Specialist Awards (Laboratory-based Scientist) Award (R50)
This FOA invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for laboratory-based scientists and is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators.

**Application Deadline:** November 1, 2021

Read More

NCI Research Specialist (Core-based Scientist) Award (R50)
This FOA invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists and is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators.

**Application Deadline:** November 1, 2021

Read More